Fitzpatrick, Cella, Harper & Scinto Announces Two New Partners

Fitzpatrick Press Release
January 9, 2018

New York, NYJanuary 2, 2018—Fitzpatrick, Cella, Harper & Scinto, one of the world’s leading intellectual property law firms, announced that, effective January 1, 2018, Christopher Gerson and Damien Dombrowski have been named partners of the firm.

“We are thrilled to welcome Christopher and Damien as partners, as each works with such a wide variety of industries within their respective intellectual property practices,” said Dominick Conde, partner and member of the Management Committee. “Christopher and Damien are extremely talented attorneys who have contributed tremendously to our firm.”

Christopher Gerson’s practice focuses on patent litigation relating to a number of technologies and industries, including computer processors and architecture, security and encryption software, mobile devices, digital cameras, photocopiers and printers, infrastructure equipment used in telephone networks, semiconductor technology, eye vitamin supplements for macular degeneration and hearing aid technology. Chris has been a member of numerous trial teams in federal courts and at the United States International Trade Commission (ITC) for various Fortune 500 clients, including leading hardware, software and telephony companies and a leading supplier of eye health products. He has also prepared inter partes review (IPR) petitions and successfully defended the validity of multiple patents challenged in IPR proceedings. Chris has a B.S.E. in electrical engineering from Princeton University and a law degree, cum laude, from NYU School of Law.

Damien Dombrowski has experience in all aspects of patent litigation, bench/jury trials and Federal Circuit appeals, on behalf of plaintiffs and defendants. His experience includes patented technologies related to pharmaceuticals and formulations for the treatment of cancer, systemic fungal infections, psoriasis, and respiratory conditions; cancer immunotherapy vaccines; eye vitamin supplements for macular degeneration; DNA sequencing technology; and hardware and software for image sensors and touchscreens/displays. He also has significant experience with due diligence, complex multiparty settlement and license agreements, license/contract disputes, and opinion work. Damien has B.S. degrees in neurobiology and biochemistry with minors in math and chemistry from the University of Washington and a law degree from Fordham University.

About Fitzpatrick, Cella, Harper & Scinto:

At Fitzpatrick, Cella, Harper & Scinto (www.fitzpatrickcella.com), IP is not just a practice area – it is the firm’s sole focus. Founded in 1971, Fitzpatrick is a leading national intellectual property law firm with offices in New York, Costa Mesa, California, and Washington, D.C. It has one of the premier patent litigation and prosecution practices, which covers the spectrum of intellectual property services, including applying for patent and trademark protection, litigation, appeals, interferences, post-grant patent challenges (e.g., IPRs), alternative dispute resolution, licensing, opinions, corporate transactions, and due diligence. Fitzpatrick represents an international client base from Fortune 500 companies to start-up companies.